



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

José Ignacio Fernández-Velasco
✉ jfvelasco@salud.madrid.org

†These authors have contributed
equally to this work and share
first authorship

RECEIVED 26 November 2024
ACCEPTED 28 November 2024
PUBLISHED 19 December 2024

CITATION

Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MA, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L and Villar LM (2024) Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis. *Front. Immunol.* 15:1535051. doi: 10.3389/fimmu.2024.1535051

COPYRIGHT

© 2024 Rodríguez-Jorge, Fernández-Velasco, Villarrubia, Gracia-Gil, Fernández, Meca-Lallana, Díaz-Pérez, Sainz de la Maza, Pacheco, Quiroga, Ramió-Torrentà, Martínez-Yélamos, Bau, Monreal, López-Real, Rodero-Romero, Borrega, Díaz, Eguía, Espiño, Chico-García, Barrero, Martínez-Ginés, García-Domínguez, De la Fuente, Moreno, Sainz-Amo, Mañé-Martínez, Caminero, Castellanos-Pinedo, Gómez López, Labiano-Fontcuberta, Ayuso, Abreu, Hernández, Meca-Lallana, Martín-Aguilar, Muriel García, Masjuan, Costa-Frossard and Villar. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

Fernando Rodríguez-Jorge^{1†},
José Ignacio Fernández-Velasco^{1,2*}, Noelia Villarrubia²,
Julia Gracia-Gil³, Eva Fernández³, Virginia Meca-Lallana⁴,
Carolina Díaz-Pérez⁴, Susana Sainz de la Maza²,
Eva María Pacheco⁵, Ana Quiroga⁶, Lluís Ramió-Torrentà⁶,
Sergio Martínez-Yélamos⁷, Laura Bau⁷, Enric Monreal¹,
Ana López-Real⁸, Alexander Rodero-Romero², Laura Borrega⁹,
Santiago Díaz¹⁰, Pablo Eguía¹⁰, Mercedes Espiño²,
Juan Luis Chico-García¹, Francisco Javier Barrero¹¹,
María Luisa Martínez-Ginés¹²,
José Manuel García-Domínguez¹², Soraya De la Fuente¹³,
Irene Moreno¹⁴, Raquel Sainz-Amo^{1,2}, M. Alba Mañé-Martínez¹⁵,
Ana Caminero¹⁶, Fernando Castellanos-Pinedo¹⁷,
Ana Gómez López¹³, Andrés Labiano-Fontcuberta¹³,
Lucía Ayuso¹⁸, Rossana Abreu¹⁹, Miguel Ángel Hernández¹⁹,
José Meca-Lallana²⁰, Lorena Martín-Aguilar²¹,
Alfonso Muriel García²², Jaime Masjuan¹,
Lucienne Costa-Frossard¹ and Luisa María Villar²

¹Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Immunology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Neurology Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain, ⁴Neurology Department, Hospital Universitario La Princesa, Madrid, Spain, ⁵Neurology Department, Hospital Universitario Juan Ramon Jimenez, Huelva, Spain, ⁶Neurology Department, Hospital Universitario de Gerona Doctor Josep Trueta, Gerona, Spain, ⁷Neurology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Neurology Department, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁹Neurology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁰Neurology Department, Hospital Universitario Gran Canaria Doctor Negrín, Gran Canaria, Spain, ¹¹Neurology Department, Hospital Universitario Clínico San Cecilio Granada, Granada, Spain, ¹²Neurology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹³Neurology Department, Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁴Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹⁵Neurology Department, Hospital Universitario Joan XXII, Tarragona, Spain, ¹⁶Neurology Department, Complejo Asistencial de Ávila, Ávila, Spain, ¹⁷Neurology Department, Hospital Virgen del Puerto, Cáceres, Spain, ¹⁸Neurology Department, Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹⁹Neurology Department, Hospital Universitario Nuestra Señora Candelaria, Tenerife, Spain, ²⁰Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²¹Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²²Biostatistics Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

KEYWORDS

multiple sclerosis, ocrelizumab, neurofilament light chain, glial fibrillary acidic protein, serum biomarkers

A Corrigendum on

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis.

By Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos-Pinedo F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L and Villar LM (2024) *Front. Immunol.* 15:1480676. doi: 10.3389/fimmu.2024.1480676

In the published article, an author name was incorrectly written as “Fernando Castellanos”. The correct spelling is “Fernando Castellanos-Pinedo”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.